We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals

222 hedge funds and large institutions have $3.01B invested in Crinetics Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 95 increasing their positions, 65 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

634% more call options, than puts

Call options by funds: $3.14M | Put options by funds: $428K

46% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 65

2.16% more ownership

Funds ownership: 109.51%111.68% (+2.2%)

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

2% less funds holding

Funds holding: 227222 (-5)

12% less capital invested

Capital invested by funds: $3.42B → $3.01B (-$412M)

33% less funds holding in top 10

Funds holding in top 10: 96 (-3)

Holders
222
Holders Change
-5
Holders Change %
-2.2%
% of All Funds
2.92%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.08%
New
35
Increased
95
Reduced
65
Closed
37
Calls
$3.14M
Puts
$428K
Net Calls
+$2.71M
Net Calls Change
+$6.76M
Name Holding Trade Value Shares
Change
Change in
Stake
SW
251
SVB Wealth
Massachusetts
-$1.44K -43 Closed
CIBC Private Wealth Group
252
CIBC Private Wealth Group
Georgia
-$818 -32 Closed
MPWT
253
MassMutual Private Wealth & Trust
Connecticut
-$1.07K -32 Closed
SC
254
Stephens Consulting
Michigan
-$1.01K -30 Closed
CFD
255
Creative Financial Designs
Indiana
-$939 -28 Closed
CA
256
Continuum Advisory
Idaho
-$839 -25 Closed
CA
257
CoreCap Advisors
Michigan
-$235 -7 Closed
AW
258
Avion Wealth
Texas
+$494 +16 New

CRNX Hedge Fund Activity: Q2 2025 in Review

222 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2025, worth a combined $3.01B — down 12% from $3.42B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of CRNX and 35 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 95 added.

The largest buyer was Point72 Asset Management, adding an estimated $37.7M. The largest seller was Wellington Management Group, cutting an estimated $33.5M.

  • 222 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2025, down from 227 in Q1 2025.
  • Funds reported $3.01B of Crinetics Pharmaceuticals stock for Q2 2025, down 12% quarter-over-quarter.
  • 35 funds opened new Crinetics Pharmaceuticals positions in Q2 2025 and 37 closed out, a net change of -2 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $37.7M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2025 was Wellington Management Group, an estimated $33.5M sold.

Based on aggregated 13F filings for Q2 2025.